Jun 23, 2026 04:09AM
Jun 23, 2026 03:00AM
Jun 16, 2026 08:15AM
Jun 16, 2026 08:01AM
Jun 16, 2026 08:00AM
Jun 8, 2026 08:01AM
Jun 8, 2026 08:00AM AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
May 27, 2026 06:18PM
May 27, 2026 06:18PM
May 27, 2026 03:38PM
May 13, 2026 08:30AM
May 13, 2026 08:30AM
May 5, 2026 08:05AM
May 5, 2026 08:05AM AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
Apr 29, 2026 07:47AM
Apr 28, 2026 08:00AM
Apr 27, 2026 08:05AM
Apr 27, 2026 08:05AM
Apr 23, 2026 04:35PM
Apr 23, 2026 04:06PM
Apr 23, 2026 04:05PM AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
Apr 12, 2026 07:15AM
Apr 12, 2026 07:15AM
Mar 31, 2026 08:05AM
Mar 27, 2026 10:00AM
Mar 12, 2026 06:55AM
Mar 2, 2026 08:30AM
Mar 2, 2026 08:30AM AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
Feb 20, 2026 05:29AM
Feb 20, 2026 02:00AM
Feb 19, 2026 05:31PM
Feb 17, 2026 05:31PM
Feb 16, 2026 05:31PM
Feb 4, 2026 07:48AM
Feb 3, 2026 08:02AM AbbVie submits vitiligo treatment application to FDA and EMA
Feb 3, 2026 08:00AM
Jan 16, 2026 01:43PM
Jan 16, 2026 01:43PM
Dec 22, 2025 07:06AM
Dec 2, 2025 08:15AM
Nov 18, 2025 12:48PM
Nov 18, 2025 12:47PM AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Nov 5, 2025 01:50PM
Oct 31, 2025 07:49AM
Oct 29, 2025 05:00PM
Oct 29, 2025 08:11AM
Oct 29, 2025 08:11AM
Oct 24, 2025 08:29AM
Oct 20, 2025 08:00AM AbbVie's RINVOQ outperforms HUMIRA in rheumatoid arthritis study
Oct 20, 2025 08:00AM

324,031 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All